Ichor has established several ongoing research and development collaborations and licensing agreements to advance the development of electroporation-mediated DNA drug delivery. Current research partners include:

Aaron Diamond AIDS Research Center	Bayhill Therapeutics	Genexine
The Johns Hopkins Bloomberg School of Public Health	Memorial Sloan-Kettering Cancer Center	Pharmexa-Epimmune
Rockefeller University	The Scripps Research Institute	The Vaccine and Infectious Disease Organization (VIDO)

We are currently pursuing a wide-range of pre-clinical and clinical studies with these and other strategic partners in the areas of Cancer, Viral Hepatitis, Multiple Sclerosis, Diabetes, and Cardiovascular Disease. The technology is also being used to develop vaccines for the prevention/treatment of HIV/AIDS, influenza, hospital acquired infections, and a number of infectious agents that are considered to be high priorities for biodefense.

We are open to exploring additional research and development partnerships that would utilize our expertise in DNA drug delivery to optimize the clinical results of new and existing DNA drugs or vaccines. We also seek partners with complementary resources and capabilities.